Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) shot up 5% during mid-day trading on Tuesday . The company traded as high as $34.91 and last traded at $34.44. 170,904 shares were traded during mid-day trading, a decline of 82% from the average session volume of 929,743 shares. The stock had previously closed at $32.79.
Analysts Set New Price Targets
A number of analysts have recently issued reports on the company. Noble Financial reiterated an "outperform" rating and set a $70.00 price target on shares of Tonix Pharmaceuticals in a research report on Thursday, March 20th. Wall Street Zen raised shares of Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, June 7th. Finally, Alliance Global Partners restated a "buy" rating on shares of Tonix Pharmaceuticals in a research report on Tuesday, June 3rd.
Check Out Our Latest Research Report on TNXP
Tonix Pharmaceuticals Trading Down 2.4%
The stock has a market capitalization of $255.29 million, a PE ratio of -0.02 and a beta of 2.09. The business has a fifty day moving average price of $28.20 and a 200-day moving average price of $24.59.
Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($2.84) EPS for the quarter, beating analysts' consensus estimates of ($3.23) by $0.39. Tonix Pharmaceuticals had a negative net margin of 1,313.87% and a negative return on equity of 120.96%. The business had revenue of $2.43 million for the quarter, compared to analysts' expectations of $2.55 million. On average, equities analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -1762.5 earnings per share for the current fiscal year.
Insider Buying and Selling at Tonix Pharmaceuticals
In related news, CEO Seth Lederman acquired 4,000 shares of the firm's stock in a transaction dated Thursday, May 15th. The shares were purchased at an average price of $21.55 per share, for a total transaction of $86,200.00. Following the completion of the acquisition, the chief executive officer now owns 4,005 shares in the company, valued at approximately $86,307.75. This represents a 80,000.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.03% of the company's stock.
Institutional Investors Weigh In On Tonix Pharmaceuticals
Institutional investors have recently bought and sold shares of the stock. Commonwealth Equity Services LLC bought a new position in shares of Tonix Pharmaceuticals during the fourth quarter valued at about $40,000. Geode Capital Management LLC boosted its position in Tonix Pharmaceuticals by 1,600.1% during the 4th quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company's stock valued at $650,000 after acquiring an additional 1,855,907 shares in the last quarter. Northern Trust Corp purchased a new position in shares of Tonix Pharmaceuticals during the 4th quarter worth approximately $162,000. Jane Street Group LLC raised its position in shares of Tonix Pharmaceuticals by 5,932.3% in the 4th quarter. Jane Street Group LLC now owns 1,662,682 shares of the company's stock worth $548,000 after acquiring an additional 1,635,119 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in shares of Tonix Pharmaceuticals in the 4th quarter valued at approximately $526,000. 82.26% of the stock is currently owned by hedge funds and other institutional investors.
Tonix Pharmaceuticals Company Profile
(
Get Free Report)
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Featured Stories
Before you consider Tonix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tonix Pharmaceuticals wasn't on the list.
While Tonix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.